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Abstract
Cancer is associated with a wide range of hereditary disorders. Recognizing these disorders in cancer patients
may be of great importance for the medical management of both patients and their relatives. Conversely,
recognizing the fact that cancer may develop as a complication of a particular hereditary disorder which has
already been diagnosed may be important for the same reason. The Familial Cancer Database (FaCD) is 
a web-based application (www.facd.info) which has been developed at our department with the intention to
assist clinicians and genetic counsellors in making a genetic differential diagnosis in cancer patients, as well as
in becoming aware of the tumour spectrum associated with hereditary disorders that have already been diagnosed
in their patients. This encyclopaedia is published in parts and discusses the disorders included in the FaCD
database in alphabetical order. It lists names, synonyms, OMIM number, mode of inheritance, associated genes,
phenotype, clinical discussion and references. The purpose of presenting this encyclopaedia in paper format is
simply that we hope that you as clinicians and researchers find it helpful to browse through it and familiarize
yourself even better with the scope of genetic disorders that have been associated with increased tumour risk.
Introduction
Cancer is associated with a wide range of hereditary
disorders. Recognizing these disorders in cancer patients
may be of great importance for the medical
management of both patients and their relatives.
Conversely, recognizing the fact that cancer may develop
as a complication of a particular hereditary disorder
which has already been diagnosed may be important
for the same reason. The Familial Cancer Database
(FaCD) is a web-based application (www.facd.info) which
has been developed at the Department of Genetics of
the University Medical Center Groningen, The
Netherlands, with the intention to assist clinicians and
genetic counsellors in making a genetic differential
diagnosis in cancer patients, as well as in becoming
aware of the tumour spectrum associated with hereditary
disorders that have already been diagnosed in their
patients. This encyclopaedia is published in parts and
discusses the disorders included in the FaCD database
in alphabetical order. It lists names, synonyms, genes
involved, phenotype, brief clinical discussion and
references. The following classes of disorders have been
included in this paper: hereditary disorders certainly or
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possibly associated with increased cancer risk (e.g. Lynch
syndrome) and familial clustering of particular types of
cancer e.c.i. (for example familial occurrence of salivary
gland tumours). If some fields are not listed for 
a particular disorder, for example ‘Non-tumour features’,
then those fields are empty for that disorder. Especially
in rare syndromes it can be difficult to decide whether
or not a particular tumour type truly belongs to the
phenotype of that disorder. Those tumours have been
classified below as ‘Tumour features (possible)’ in the
descriptions of the phenotypes. The purpose of
presenting this encyclopaedia in paper format is that we
hope that you as clinicians and researchers find it helpful
to browse through it and familiarize yourself even better
with the scope of genetic disorders that have been
associated with increased tumour risk.
Abbreviations used:
AD – autosomal dominant
AR – autosomal recessive
CGD – contiguous gene deletion
CI – confidence interval
de novo – de novo mutation
Impr – subject to genomic imprinting
Multifact – multifactorial inheritance
OMIM number – the number of the disorder in Online
Mendelian Inheritance in Men
Pat – paternal
RR – relative risc
SIR – standarized incidence ratio
Upd – uniparental disomy
XLR or XLD – X-linked recessive or dominant, respectively




Synonym: AIMAH, Cushing’s disease, adrenal, familial
Mode of inheritance: spor/AD
OMIM number: 219080
Genes:







AIMAH cases are usually sporadic, causing
Cushing’s disease generally in the 5th or 6th decade.
Affected siblings with Cushing’s disease caused by
primary (ACTH independent) adrenal, often bilateral,
nodular hyperplasia and dysplasia have been observed
[1-5]. Somatic GNAS1 mutations have been observed
in isolated AIMAH cases.
References
1. Christopoulos S, Bourdeau I, Lacroix A. Clinical and subclinical
ACTH-independent macronodular adrenal hyperplasia and
aberrant hormone receptors. Horme Res 2005; 64: 119-131.
2. Donaldson MD, Grant DB, O’Hare MJ, Shackleton CH.
Familial congenital Cushing’s syndrome due to bilateral
nodular adrenal hyperplasia. Clin Endocrinol (Oxf) 1981; 14:
519-526.
3. Hodge BO, Froesch TA. Familial Cushing’s syndrome.
Micronodular adrenocortical dysplasia. Arch Intern Med 1988;
148: 1133-1136.
4. Findlay JC, Sheeler LR, Engeland WC, Aron DC. Familial
adrenocorticotropin-independent Cushing’s syndrome with
bilateral macronodular adrenal hyperplasia. J Clin Endocrinol
Metab 1993; 76: 189-191.
5. Teding van Berkhout F, Croughs RJ, Wulffraat NM, Drexhage
HA. Familial Cushing’s syndrome due to nodular adrenocortical
dysplasia is an inherited disease of immunological origin. Clin
Endocrinol (Oxf) 1989; 31: 185-191.
Acute lymphoblastic leukaemia, familial
clustering of
Synonym: familial ALL, including familial T-ALL
Mode of inheritance: AD?/multifact?
Genes:
CYP1A1, mapped to 15q22-q24
GSTM1, mapped to 1p13.3
HLA-DQB1, mapped to 6p21.3
Tumour features:
leukaemia, acute lymphoblastic (ALL)
Comment
Familial clustering of ALL has been observed [1-3].
Becker et al. [4] reported a 4-generation Irish family
with childhood onset acute T-cell leukaemia/
lymphoblastic T-cell lymphoma in 9 relatives, which to
the authors suggested autosomal dominant inheritance
with reduced penetrance.
Dearden et al. [5] studied HLA-DQB1 alleles in
children with ALL because of the suggestion that ALL
may be caused by HLA-regulated susceptibility to an
unidentified neonatal infection. They observed 
a significant excess of the DQB1*05 allele (RR 2.5)
and in particular of certain amino acid motifs (not
restricted to that allele). Polymorphisms in the GSTM1
and CYP1A1 genes, encoding xenobiotic-metabolizing
enzymes, have been found to be associated with an
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increased relative risk of childhood ALL [6]. A germline
heterozygous truncating mutation in the gene for
Fanconi anaemia type C has been detected in 2 sibs
with T-ALL; 1 of the sibs subsequently developed AML
[7]. In general, there appears to be no increase in ALL
risk to siblings of patients. Risk may even be decreased
and it has been speculated that immunization of
mothers to leukaemia-specific antigens may occur
which can enhance elimination of pre-leukaemic cells
in utero [8].
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Acute myelocytic leukaemia with
polyposis coli and colon cancer





leukaemia, acute myeloblastic (AML, M2)
Comment
Two brothers with consanguineous parents were
reported by Greenberg et al. [1] to have developed
multiple colorectal adenomatous polyps, early-onset
colorectal cancer, acute myeloblastic leukaemia, and 
(in one of the brothers) papillary bladder tumours. This
could have been a case of bi-allelic MMR gene mutations.
References
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Adenosine deaminase deficiency
Synonym: severe combined immunodeficiency (SCID)
due to ADA deficiency
Mode of inheritance: AR
OMIM number: 102700
Genes:












A substantial percentage of (apparently) autosomal
recessive severe combined immunodeficiency is caused by
deficiency of adenosine deaminase. Dysplastic skeletal
changes (typically of costochondral junctions) occur
frequently in patients with ADA deficiency. Most cases are
diagnosed in the first year [1]. As in other types of severe
combined immune deficiency, there is an increased risk of
developing malignancies of the haemato-lymphoproliferative
type [2-5]. There appears to be no increased cancer risk
for heterozygotes of the mutant gene [6].
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Agammaglobulinaemia, X-linked
Synonym: Bruton type agammaglobulinaemia
Mode of inheritance: XLR
OMIM number: 300300, 300310
Genes:




leukaemia, acute lymphoblastic (ALL)










This infantile immunodeficiency in males is
characterized by an isolated B-cell defect and these cells
are absent in the vast majority of patients. Lymphoid
tissue (adenoid, tonsils) is either absent or hypoplastic.
There is approximately an incidence of 1.5-6% of
malignancies in this disorder, mainly involving the
haematopoietic-lymphoid system [1-9]. Patients also
have an increased risk of developing colorectal cancer
[10,11]. Lung cancer was diagnosed in a 32-year-old
non-smoking male with the disorder [12]. Gastric cancer
associated with chronic atrophic gastritis [13, 14].
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Aicardi syndrome
Mode of inheritance: XLD
OMIM number: 304050
Genes:









palate, benign teratoma of
parapharyngeal embryonal cell cancer
Encyclopaedia of tumour-associated familial disorders. Part I: from AIMAH to CHIME syndrome















Clinical hallmarks are infantile spasms, corpus
callosal agenesis, chorioretinal abnormalities (lacunae)
and severe psychomotor retardation. Other findings
include plagiocephaly, facial asymmetry, cleft lip and
palate and costovertebral anomalies. A number of
tumours have been reported in association with Aicardi
syndrome [1-7]: choroid plexus papilloma (the most
frequent tumour), medulloblastoma, gastric hyperplastic
polyps, rectal polyps, soft palate benign teratoma,
hepatoblastoma, parapharyngeal embryonal cell
cancer, limb angiosarcoma and scalp lipoma.
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Alagille syndrome
Synonym: ALGS1, ALGS2, Alagille-Watson syndrome
Mode of inheritance: AD/AR?
OMIM number: 118450
Genes:
JAG1, mapped to 20p12



















Hallmarks of this disorder are: paucity of
intrahepatic bile ducts leading to cholestasis,
peripheral pulmonary artery stenosis, vertebral arch
defects, poor linear growth, a characteristic facies
and embryotoxon posterior in the eye [1].
Hepatocellular cancer has been reported in a number
of cases [2-5], and papillary thyroid cancer [6] and
Wilms’ tumour in one case [7].
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Alpha-1-antitrypsin deficiency
Mode of inheritance: AD
OMIM number: 107400
Genes:










This disorder is caused by deficiency of alpha-1-
antitrypsin (= protease inhibitor = anti-elastase) and
is characterized by emphysema and juvenile or adult
liver cirrhosis. The severity of the disease depends on
the specific combination of alleles and very likely also
on the influence of exogenous factors such as smoking.
The homozygous null allele combination causes the
most severe disease, followed by the ZZ combination.
Risk of hepatocellular cancer is increased, possibly only
in males [1, 2] and depending on allele type [3]. It has
been reported in children [4]. Alpha-1-antitrypsin
deficiency/haplosufficiency may also act as a co-risk
factor for lung cancer [5]. Yang et al. [6] estimated 
a 20-fold increase in risk of developing colorectal cancer
(with microsatellite instability, MSI-H) among smokers
who carry alpha-1-antitrypsin deficiency alleles.
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Mode of inheritance: AD
OMIM number: 104150
Genes:







This disorder is characterized by the persistence of
high AFP, due to a mutation in the AFP gene [1, 2].
Staples et al. [3] reported high serum AFP in a 23-year-
old man with a testicular seminoma as well as in his 
3 sisters, mother and maternal aunt. He also had
hereditary spherocytosis. Hart et al. [4] and Cochran et
al. [5] reported a yolk sac tumour in a 20-year-old male
and a 20-month-old male with HPAFP, respectively.
Although the association is probably purely coincidental,
it is important to stress that HPAFP may confuse
management in patients with testicular or liver tumours,
or other conditions where AFP levels are of diagnostic or
screening importance. If HPAFP is not recognized in these
conditions, then this may lead to inappropriate medical
decisions. Testing parental levels of AFP has been advised
for cases where persistent (mild) elevation of AFP
following resection of localized germ cell tumours has
been observed, before deciding on chemotherapy [5].
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Alport syndrome with diffuse
leiomyomatosis
Mode of inheritance: XLD/cgd
OMIM number: 308940
Genes:
COL4A5, mapped to Xq22-q24
COL4A6, mapped to Xq22-q24
Tumour features:
bronchioli, leiomyoma of the
oesophageal leiomyoma
gastric leiomyoma
leiomyoma of the clitoris
leiomyoma of the urethra








Alport syndrome is characterized by haematuric
nephropathy, in most cases leading to renal failure (usually
progressive), sensorineural deafness and ocular anomalies
(maculopathy and anterior lenticonus). Some patients with
Alport syndrome develop diffuse leiomyomatosis (especially
of the oesophagus and less often the vulva and other
anatomical sites). These patients also frequently have
severe cataracts. The oesophageal leiomyomas appear
to develop earlier among boys (average age 6 years
compared to 14 years in girls) [1-4].
Alport syndrome is genetically heterogeneous. The
specific subset of patients/families with Alport syndrome
and leiomyomatosis is associated with deletions
extending from within the COL4A5 gene to the
neighbouring COL4A6 gene [5, 6]. Multiple giant
gastro-oesophageal leiomas have been reported in
the absence of such a detectable deletion [7].
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Amenorrhoea-galactorrhoea syndrome





Familial cases of galactorrhoea and amenorrhoea,
due to a pituitary gland tumour, have been reported
[1, 2]. Possibly these cases represent in fact multiple
endocrine neoplasia type 1 or another type of
hereditary pituitary gland tumours.
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Androgen insensitivity syndrome
Synonym: AIS, testicular feminisation, Reifenstein
syndrome
Mode of inheritance: X-linked
OMIM number: 300068
Genes:
AR, mapped to Xq11-q12









Mutations in the androgen receptor coding gene on
the X chromosome cause pseudo-hermaphroditism in
the XY individual through androgen insensitivity. External
genitals are female. The gonads are undescended testes
and may be intra-abdominal, inguinal, or labial.
Mullerian structures (including uterus) are absent, because
of AMH production by the testicles [1].
Sex cord hamartomas and Sertoli cell adenomas are
common findings in AIS, with a prevalence of 63 and
23%, respectively, observed in one series of 43 patients
[2]. Patients with AIS show an increased frequency of
testicular malignancies with risks estimated between 
2 and 33%; 2-10% might be the most realistic estimate.
Seminoma [3-8] and sex-cord stromal tumours
(particularly Sertoli-cell tumours) [9-14] are the most
common tumour types observed. Gonadoblastoma [15]
and non-seminomas (yolk sac tumour [16], embryonal
carcinoma [17]) have been reported as well.
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Angiolipomatosis, familial







Familial clustering of multiple (non-infiltrating)
angiolipomas has been reported a few times, the most
extensive family being that published by Kumar et al. [1].
In that family the angiolipomas were well encapsulated
and located on the upper part of the body. Hapnes et al.
[2] reported on a case with angiolipomas located close
to joints and extending deep between muscle, tendons and
joint capsules. Abbasi et al. reported an 80-year-old man
with a 50-year history of asymptomatic, subcutaneous
masses on the arms, trunk, and legs. His father and
maternal grandmother had a history of similar lesions
[3]. The distinction from familial multiple lipomatosis is
not completely certain. Familial angiolipomatosis may
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sometimes be clinically confused with neurofibromatosis
type 1 (NF1). Interestingly, Cina et al. [4] reported the
occurrence of Lisch nodules (a typical feature of NF1) 
in familial angiolipomatosis.
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Arrhenoblastoma and thyroid adenoma,
familial
Synonym: including arrhenoblastoma, familial
clustering
Mode of inheritance: AD
OMIM number: 107950
Tumour features:
ovarian Sertoli-Leydig cell tumour
thyroid adenoma
Tumour features (possible):






A number of families with multiple cases of ovarian
Sertoli-Leydig cell tumours (arrhenoblastomas) have
been reported. In some of these families (multiple)
thyroid adenomas were also present in some of the
relatives with ovarian tumours as well as in relatives
without these tumours [1, 2]. A mucinous cystadenoma
was reported twice in these families and one case of
Wilms’ tumour was reported [1]. In the proband
published by O’Brien et al. [2], a hamartous polyp was
removed from the small intestine at the age of 
3 months. Could this disorder be a variant of Cowden
syndrome or Peutz-Jeghers syndrome?
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Ataxia pancytopenia syndrome
Synonym: myelocerebellar disorder





bone marrow monosomy 7 karyotype
cerebellar ataxia
nerve conduction velocity, reduced
pancytopenia
Comment
This condition is characterized by pancytopenia,
progressive cerebellar ataxia, reduced nerve conduction
speed and acute myelomonocytic leukaemia, which all
develop in early childhood. The hypoplastic bone marrow
shows cells with a monosomy 7 karyotype [1-3].
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Ataxia telangiectasia
Synonym: AT, Louis-Bar syndrome
Mode of inheritance: AR
OMIM number: 208900
Genes:











leukaemia, acute lymphoblastic (ALL)
leukaemia, chronic lymphocytic (CLL)
non-Hodgkin’s lymphoma
ovarian cancer (i.e. epithelial origin)
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parotid gland cancer
skin cancer, basal cell
skin cancer, squamous cell
thyroid cancer
Tumour features (possible):




















Progressive ataxia usually develops during infancy.
Telangiectasia occurs usually first in the bulbar
conjunctivae and later over the bridge of the nose,
auricles and other areas. Growth deficiency commonly
presents during late infancy/childhood. Mental
deficiency is a feature in about half of cases [1].
Neoplasms develop in approximately 10 percent of
patients, especially lymphoid tumours. Many patients
do not survive to adulthood, lung infections and
neurological complications being the main cause of
death. Non-Hodgkin’s lymphoma (mostly of the
histological subtype associated with 14q translocations),
acute lymphoblastic leukaemia and Hodgkin’s disease
(mostly of lymphocytic depletion type) are the most
frequent neoplasms in AT patients [2]. Myeloid tumours
are absent [3]. The increase in lymphoid malignancy
is caused by both B- and T-cell tumours [3, 4]. T-cell
tumours may develop at any age and may be T-ALL,
T-cell lymphoma or T-cell prolymphocytic leukaemia
[3]. The recognition of lymphomas may be delayed
due to confusion with known infectious complications
in AT [5]. A wide range of other neoplasms have been
reported, including gastric cancer, colon cancer,
chronic lymphoblastic leukaemia, brain tumours,
craniopharyngioma, liver cancer, laryngeal cancer,
leiomyoma and leiomyosarcoma of the uterus,
dysgerminoma, fibroadenoma and gonadoblastoma
of the ovaries, testicular seminoma and basal cell and
squamous cell skin cancer [5-13].
Inheriting one mutated copy of the AT gene (ATM)
increases breast cancer risk in females, and may turn
out to contribute significantly to the total breast cancer
burden. However, data are inconclusive as to the
magnitude of this contribution and strength of this risk
factor [14-25]. Broeks et al. [26] found the relatively
high percentage of 8.5% ATM mutation carriers in 
a group of 82 breast cancer patients selected for early
onset (<45 years), long-term survival and bilaterality.
Baynes et al. showed that it is unlikely that common
ATM variants increase breast cancer risk [27]. Johnson
et al. confirmed this and argued that it is rather 
a combination of variants in different genes (ATM,
BRCA1, BRCA2) that confers an increased breast
cancer risk [28]. However, single rare ATM alleles may
still confer a substantially increased breast cancer risk
[29]. Balleine et al. reported that breast cancer
occurring in carriers of ATM variants is not associated
with distinctive histopathological features [30].
Fibroblast cultures of AT heterozygotes show
increased radiosensitivity and given the fact that breast
cancer is a complication well known to occur in long-
term survivors of Hodgkin’s disease who received
mantle-field irradiation, it has been questioned
whether germline mutations in ATM contributed to this
increase of breast cancer risk. Studies by Broeks et al.
[31] and Nichols et al. [32] did not support a major
contribution of germline ATM mutations to the breast
cancer risk in these types of patients. The same was
true for contralateral breast cancer risk after radiation
therapy for the first breast tumour, as reported by
Shafman et al. [33].
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Autoimmune lymphoproliferative
syndrome, type I
Synonym: Canale-Smith syndrome, ALPS type I
(including: ALPS1A, ALPS1B), including autoimmune
lymphoproliferative disease (ALD)
Mode of inheritance: AD
OMIM number: 601859, 134637
Genes:
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Comment
This disorder develops in early childhood because
of a defective lymphocyte apoptosis. It is characterized
by non-malignant lymphadenopathy, splenomegaly
and autoimmune disease [1]. In the majority of patients
a heterozygous mutation in APT1 has been detected.
APT1 encodes the Fas protein, which is a mediator of
lymphocyte apoptosis. Of 46 ALPS1 patients with APT1
mutations studied at the NIH, 6 (13%) developed 
a lymphoma: Hodgkin’s, Burkitt’s, follicular lymphoma
or non-Hodgkin’s lymphoma [2, 3]. A case of
hepatocellular carcinoma has also been reported. In
general, risk for non-Hodgkin’s lymphoma and
Hodgkin’s disease is increased.
Ramenghi et al. [4] reported an ALPS-like disorder,
which they referred to as autoimmune lymphoproliferative
disease (ALD), associated with decreased Fas function in
the absence of detectable Fas mutations. Hodgkin’s
disease was reported by them to have occurred in one
of these ALD families and the frequency of cancer in
general was increased in the families’ maternal lines.
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Mode of inheritance: AR
OMIM number: 240300
Genes:
AIRE, mapped to 21q22.3
Tumour features:
oesophagus, squamous cell cancer of the














This rare autoimmune disorder mainly affects the
endocrine glands [parathyroid glands (85%), adrenal
cortex (72%) and ovaries (60%)] and is associated with
enamel hypoplasia (77%), nail dystrophy (52%),
keratopathy (22%) and candidiasis (100%). Oral
squamous cell cancer and severe autoimmune hepatitis
are the most life-threatening complications [1-3].
Perheentupa reported oral or oesophageal squamous
cell carcinoma in 10% of patients older than 25 years
in a relatively large Finnish series [4].
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Bannayan-Riley-Ruvalcaba syndrome
Synonym: subset of PTEN-MATCH, including
Ruvalcaba-Myhre-Smith syndrome
Mode of inheritance: AD
OMIM number: 153480
Genes:
PTEN, mapped to 10q23.3
Tumour features:
facial papules
hamartomatous polyps in colon/rectum
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Lipid storage myopathy, pigmented macules on
glans and shaft of penis and vulva, intestinal hamartous
(juvenile type) polyps and neurodevelopmental delay
are the typical features [1-9]. A clinical overlap with
Cowden disease has been noted and indeed germline
mutations in the PTEN gene, involved in Cowden
disease, have been detected in this disorder. It should
therefore be considered as a variant of Cowden
syndrome [10-15]. DiLiberti [10] has recently proposed
the nomenclature PTEN-MATCHS (macrocephaly,
autosomal dominant, thyroid disease, cancer,
hamartomata, skin abnormalities) to cover the clinical
spectrum associated with germline PTEN mutations.
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Bardet-Biedl syndrome
Synonym: BBS, Bardet-Biedl syndrome, type 1-12:
BBS1-12
Mode of inheritance: AR
OMIM number: 209901, 209900, 600151, 600374,
603650, 605231
Genes:
BBS1, mapped to 11q13
BBS10, mapped to 12q
BBS11, mapped to 9q33.1
BBS12, mapped to 4q27
BBS2, mapped to 16q21
BBS3, mapped to 3p12-q13
BBS4, mapped to 15q22.3
BBS5, mapped to 2q31
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BBS6/MKKS, mapped to 20p12
BBS7, mapped to 4q27
BBS8, mapped to 14q32.11
BBS9, mapped to 7p14
Tumour features (possible):














This disorder (BBS) is characterized by postaxial
polydactyly, central obesity, rod-cone dystrophy, mental
retardation and renal dysfunction. Beales et al. [1]
observed 3 cases of clear cell renal cell carcinoma
(diagnosed at age 37, 40 and 52, respectively) among
180 parents of BBS patients. This is more than
expected in the normal population (p=0.0007). The
authors calculated that parents of BBS children have
a relative risk of 17 (95% CI=3.6-49.9) of developing
clear cell renal cell cancer before the age of 55 years.
One of the tumours showed loss of heterozygosity at
the BBS1 locus. The authors suggest that the BBS genes
may be implicated in the development of renal cancer
(and renal malformation). In contrast, Hjortshøj et al.
found no evidence for an increased cancer risk in BBS
patients and their relatives [2].
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Barrett’s oesophagus, familial
Mode of inheritance: AD?/multifact?
OMIM number: 109350
Tumour features:









Barrett’s oesophagus and oesophageal
adenocarcinoma are complications of gastroesophageal
reflux [1], which may show familial clustering, as has
been demonstrated by Romero et al. [2]. These authors
reported that reflux symptoms were significantly more
prevalent among parents and siblings of patients with
oesophageal adenocarcinoma and/or Barrett’s
oesophagus than among controls. Other authors have
reported familial cases as well. Hampel et al. [3]
reported on 3 families and suggested that Barrett’s
oesophagus families possibly are at an increased risk
of developing extra-oesophageal cancer (notably of the
digestive tract) as well. More recently more familial
clusters have been reported [4-8] and family history is
an acknowledged risk factor. Chak et al. showed that 
a family history of Barrett’s oesophagus can be
confirmed in 7.3% of persons presenting with Barrett’s
oesophagus, adenocarcinoma of the oesophagus, or
adenocarcinoma of the gastroesophageal junction [5].
Linkage analyses are underway [9].
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Basal cell nevus syndrome
Synonym: Gorlin syndrome, Gorlin-Golz syndrome,
naevoid basal cell carcinoma syndrome
Mode of inheritance: AD
OMIM number: 109400
Genes:
PTCH, mapped to 9q22.3
Tumour features:
cardiac fibroma
infundibulocystic basal cell cancer
medulloblastoma
ovarian fibroma









leukaemia, acute lymphoblastic (ALL)














salivary gland, adenoid cystic carcinoma
seminoma







falx cerebri, calcification of
frontoparietal bossing
hypertelorism
ionizing radiation sensitivity, increased












In this disorder, multiple nevoid basal cell cancers
(NBCC) typically start to appear at the age of puberty,
although they have been reported to occur as early
as 3 years of age. The NBCCs may manifest anywhere
on the skin, but mainly on the face, neck and upper
trunk. A typical facies is often present (70%), featuring
frontoparietal bossing, broad nasal bridge and
prognathism. Skeletal anomalies are often detected
(e.g. 80% of patients are diagnosed with keratocysts
of the jaw before the age of 30), as well as
palmoplantar skin pits (87% of patients [1]). Mental
deficiency occurs in a few cases [1-4].
A wide range of tumours has been reported in basal
cell nevus syndrome in addition to basal cell
carcinomas: ovarian fibromas occur in frequencies
ranging from 14 to over 50%. Medulloblastoma, ages
at diagnosis ranging from 2 months to 7 years and of
the desmoplastic subtype [5], is considered to be part
of the tumour spectrum [6] and has been included as
a minor criterion for the disorder (see below). However,
it is still relatively rare: 4 out of 105 patients studied
by Kimonis et al. [1]. Cardiac fibromas [7, 8] have
been included as a minor criterion as well. Other
reported tumours include: rhabdomyosarcoma [9, 10],
(malignant) meningioma [1, 11], astrocytoma
[4, 12, 13], cerebellar ependymoma [1], hamartous
polyps of the stomach [14], fetal rhabdomyoma [15],
nasal dermoid cyst [16], NHL [4], ovarian dermoid cyst
[4], CLL [4], ALL [13], breast cancer [4], lung cancer
[4], ovarian fibrosarcoma [2] and ovarian
leiomyosarcoma [17], leiomyosarcoma of the
extremities [18], seminoma [19], carcinoma of the vulva
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[20], adenoid cystic carcinoma of the salivary glands
[21] and others [2]. Rhabdomyosarcoma and Wilms’
tumour were diagnosed in a girl with a deletion
of 9q22-q32 which included the PTCH gene [22].
Patients with the syndrome have an increased risk
of developing secondary tumours in the field of
radiation treatment. A conservative estimate of the new
mutation rate in basal cell nevus syndrome is 14% [4].
Fukushima et al. [23] reported the occurrence of
a meningioma after radiation treatment for
a medulloblastoma.
The gene for basal cell nevus syndrome has been
identified as the human homologue of the Drosophila
patched gene [24, 25].
Diagnostic criteria:
two major criteria or one major + two minor criteria
should be present.
Major:
• multiple basal cell carcinomas, or one under the age
of 30 years, or >10 basal cell nevi; in a sunny
climate these numbers should be higher (not further
specified),
• histologically proven odontogenic keratocyst, or
polyostotic bone cyst,
• >3 palmar and/or plantar pits,
• calcification of the falx cerebri: lamellar or early
(<20 years),
• first-degree relative with nevoid basal cell
carcinomas.
Minor:
• congenital skeletal anomaly: bifid, fused, splayed or
missing rib or fused vertebrae,
• macrocephaly (occipitofrontal circumference > 97th
centile) with bossing,
• cardiac or ovarian fibroma,
• medulloblastoma,
• lymphomesenteric cysts,
• congenital malformation: cleft lip and/or palate,
polydactyly, eye anomaly (cataract, coloboma,
microphthalmia).
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Basal or squamous cell skin cancer,
familial clustering of
Synonym: familial non-melanoma skin cancer
Mode of inheritance: multifact?
Genes: many low penetrant gene mutations have been
reported, we do not list them separately here
Tumour features:
skin cancer, basal cell
skin cancer, squamous cell
Tumour features (possible):
malignant melanoma, cutaneous
melanoma, uveal (choroidal, ciliary body, iris)/ocular
Comment
The influence of a family history of skin cancer on
basal cell skin cancer (BCC) risk is controversial. Two
studies could not demonstrate a familial risk factor 
[1, 2]. However, Wallberg et al. [3] found a family history
of skin cancer (not further specified) among siblings
and/or parents to be the strongest risk factor (RR 10.9)
of 12 factors tested. The authors could not explain this
risk by correcting for hereditary pigmentary
characteristics, such as skin type, eye and hair colour,
which are known to be associated with melanoma as
well as non-melanoma skin cancer risk [4]. Hogan et
al. [5] also found that a family history of skin cancer
was associated with an increased risk of developing
BCC (RR 1.22). In their series of 538 BCC patients 
and matched controls, they also observed 
a significantly lower age at diagnosis in those BCC
patients with a family history of skin cancer compared
with those who did not. In a case-control study of
similar size, Naldi et al. [6] confirmed the significant
association of BCC and a family history of skin cancer
(odds ratio 6.7). In a population-based cohort study
of twins, the co-twin of a twin affected with BCC cancer
was shown to have an increased BCC risk (RR 7-8);
however, zygosity did not influence this risk [7, 8]. In
general, BCC in children in the absence of known
genetic conditions is rare, but has been diagnosed at
the age of 4 years and older [9].
Polymorphisms of members of the glutathione-S-
transferase and cytochrome P450 enzyme families have
been associated with an increased risk of developing
(multiple) BCC [10-12].
For squamous cell skin cancer (SCC), a positive
family history of skin cancer in general also increases
SCC risk, as has been calculated by Hogan et al. [13],
Gamble et al. [14] and Hemminki and Dong [15]. The
latter study from the Swedish Family-Cancer Database
reported SIRs of 2.4 for invasive SCC and 2.8 for
invasive SCC in the offspring of parents with SCC. SIR
for SCC in offspring of parents with multiple SCC was
70% higher than in offspring of parents with single
SCC. The authors also reported a familial association
between SCC and skin and ocular melanoma.
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Bazex syndrome
Synonym: Bazex-Dupré-Christol syndrome
Mode of inheritance: XL
OMIM number: 301845
Genes:
BZX, mapped to Xq24-q27
Tumour features:
skin cancer, basal cell
Non-tumour features:






This syndrome is characterized by multiple basal cell
cancers developing mainly on the face, from the second
decade. The skin shows follicular atrophoderma
(resembling ice pick marks), especially on the face,
hands, elbows and feet. Sweating is decreased and
hypotrichosis is another characteristic. The term follicular
atrophoderma appears inappropriate because the skin
histology does not show atrophy [1-7]. The disorder
has been mapped to Xq [8].
Confusingly, the name Bazex syndrome is also used
for the sporadic disorder acrokeratosis paraneoplastica,
which mainly occurs in males and is characterized by
psoriasiform skin lesions of predominantly ears, fingers,
nose and toes, associated with squamous cell cancer
of the upper aerodigestive tract [9].
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Beckwith-Wiedemann syndrome
Synonym: BWS, exomphalos-macroglossia-gigantism
(EMG) syndrome, Wiedemann-Beckwith syndrome,
WBS
Mode of inheritance: AD/spor/impr (UPDpat11)
OMIM number: 130650
Genes:
H19, mapped to 11p15.5
LIT1/KCNQ1OT1, mapped to 11p15.5
NSD1, mapped to 5q35













leukaemia, acute lymphoblastic (ALL)
leukaemia, acute myeloid (AML, including ANLL)
lipoma
lymphoma, malignant (Non-Hodgkin and/or Hodgkin)
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Gigantism, macroglossia, omphalocele and ear
creases are the typical features of the syndrome [1-4].
Pancreatic hyperplasia often occurs and leads to
neonatal hypoglycaemia in 30-50% of cases.
Approximately 5% of children with this disorder develop
tumours before the age of 8 years, mainly Wilms’
tumour (60%), hepatoblastoma and neuroblastoma,
but a range of other tumours have been reported [2, 5-
19]. Limb asymmetry/hemihypertrophy is associated
with an increased risk of tumours [10, 11] and
nephromegaly appears to be a predictor of Wilms’
tumour, particularly in these patients [12].
The genetics of BWS are relatively complex.
Cooper et al. analysed genotype-cancer phenotype
associations and concluded that the risk of neoplasia
was significantly higher in UPD and IC1 defect cases
than in IC2 defect and CDKN1C mutation cases.
Cancer risk for all patients was estimated at 9% at
age 5 years, and 24% in the UPD subgroup. UPD
including WT1 was associated with renal neoplasia.
In contrast, Wilms’ tumour risk in the IC2 defect
subgroup appears to be small [20]. Rump et al.
concluded that increased tumour risk in BWS is
typically associated with loss of imprinting of H19 [21].
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Biallelic mismatch repair gene
mutations associated early onset cancer
Synonym: childhood cancer syndrome
Mode of inheritance: AR
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Genes:
MLH1, mapped to 3p21.3
MSH2, mapped to 2p21-p22
MSH6, mapped to 2p16







leukaemia, acute lymphoblastic (ALL)
leukaemia, acute myeloid (AML, including ANLL)













Multiple café-au-lait spots, axillary freckling and
early onset colorectal cancer, oligopolyposis,
leukaemia (ALL, AML, AL-not specifed, CML),
non-Hodgkin’s lymphoma, brain tumours
(glioblastoma, astrocytoma, oligodendroglioma
medulloblastoma), Wilms’ tumour, ovarian
neuroectodermal tumour, endometrial cancer and
sometimes IgA-deficiency have been observed in
patients with biallelic mutations of the mismatch repair
(MMR) genes MLH1, MSH2, MSH6 and PMS2 [1-11].
There is overlap with HNPCC (associated with
single inherited MMR mutations) and Turcot syndrome
(brain tumours and colorectal polyps).
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Biliary tract cancer, familial clustering of
Synonym: including familial gallbladder cancer
Mode of inheritance: multifact?
Tumour features:




A Spanish-Italian study demonstrated an
association between a family history of gallbladder
cancer and the development of this tumour in a
relative (RR 13.9) [1]. Hemminki et al. [2] studied the
occurrence of cancer in relatives of patients with liver
or biliary tract cancers. The authors demonstrated a
high risk for familial gallbladder cancer (SIR 5.21
[95% CI 2.07-10.80]) and for familial hepatocellular
cancer (SIR 4.69 [95% CI 1.48-11.04]). For
Encyclopaedia of tumour-associated familial disorders. Part I: from AIMAH to CHIME syndrome
Hereditary Cancer in Clinical Practice 2008; 6(1)42
Rolf H. Sijmons
gallbladder and hepatocellular cancer, maternal
transmission appeared to be more prevalent.
Gallbladder cancer was associated with pancreatic
cancer (SIR 2.39 [95% CI 1.23-4.18]).
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Birt-Hogg-Dubé syndrome
Synonym: fibrofolliculomas with trichodiscomas and
acrochordons, including Hornstein-Knickenberg
syndrome, perifollicular fibromatosis
Mode of inheritance: AD
OMIM number: 135150
Genes:







chromophobe renal cell cancer
colon cancer
colorectal polyps
renal cell cancer, clear-cell







This condition is characterized by the presence of
3 types of benign skin tumours: fibrofolliculomas,
trichodiscomas and acrochordons [1-4], although its
has been questioned whether acrochordons truly
belong to this hereditary disorder [5]. Spontaneous
pneumothorax and cystic lung disease is another
feature of BHD [6].
In one large family with this disorder, medullary
thyroid cancer was diagnosed in several relatives, 2
of them also presenting with skin tumours. It may have
been a coincidental co-segregation of familial
medullary thyroid cancer (see that entry) and Birt-
Hogg-Dubé syndrome. Benign and malignant
adenomatous colon polyps have been reported in
patients with this disorder and with what some consider
to be a variant of Birt-Hogg-Dubé syndrome:
Hornstein-Knickenberg syndrome, which is
characterized by multiple perifollicular fibromas [7-
10]. Renal tumours (single or multiple, unilateral 
or bilateral) of various histology have been observed
in Birt-Hogg-Dubé syndrome: oncocytoma, chro-
mophobe carcinoma and clear cell as well papillary
renal cell carcinomas [11-13].
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Bladder, ureter, renal pyelum cancer,
familial clustering of
Mode of inheritance: multifact?
Genes: many low penetrant gene mutations have been








Familial clustering of bladder cancer has been
reported [1-5] and may occur in approximately 4% of
cases [6]. Kantor et al. [6] demonstrated that having an
affected first-degree relative increases the risk of bladder
cancer. These authors reported relative risks of 2.7, 1.7
and 1.3 depending on the age at diagnosis of the
tumour: below age 45, ages 45-64 and 65 and older,
respectively. Cigarette smoking in the setting of a family
history of bladder cancer was shown to strongly increase
the risk of developing this tumour. Relative risks of up to
28.1 in heavy smokers (60 + cigarettes/day) were
calculated as compared to a RR of 2.1 in heavy smokers
with a negative family history. Non-smokers with a positive
family history still had a RR of 1.5 and this observation
of a familial component independent of smoking was
supported by the findings of Kramer et al. [7], who
reported a RR of 1.8 for a similar group. Piper et al. [8]
found bladder or renal cancer in first-degree relatives
not to be a risk factor for bladder cancer in young women
(<50 years). A family history of cancer in general has
been reported to be a risk factor in the development of
bladder cancer [2].
Having blood type A or HLA types Cw4 and B5
increases the risk of developing this tumour [9]. Inherited
variation in the metabolism of (pro)carcinogens, related
to smoking and other environmental exposures, also
influences the risk of bladder cancer, e.g. activities of
glutathione-S-transferase, N-acetyltransferase and those
of the cytochrome P450 group [10-13]. Also, certain
alleles of the Hras1 minisatellite locus are associated with
an increased tumour risk at this anatomical site [14]. More
mutations have been reported, not listed in this brief
overview. A small number of published families suggest
the existence of a rare autosomal dominant predisposition
to urinary tract cancer [3, 5, 15]. Familial clustering of
transitional cell carcinomas (TCC) at different sites of the
urinary tract has been observed [5, 16, 17], including
familial cancer of the ureter [18]. A germline translocation
(5;20)(p15;q11) has been observed in a 29-year-old man
with TCC bladder cancer. His mother had been diagnosed
with a similar tumour (she was not karyotyped) [19].
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Bloom syndrome
Mode of inheritance: AR
OMIM number: 210900
Genes:
BLM, mapped to 15q26.1
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leukaemia, acute lymphoblastic (ALL)
leukaemia, acute myeloid (AML, including ANLL)
lymphoma, malignant (non-Hodgkin’s and/or Hodgkin’s)
oral cancer













hyperpigmentation of the skin
hypopigmentation of the skin
immunodeficiency
increased chromosomal breakage




UV radiation sensitivity, increased
Non-tumour features (possible):
bone marrow monosomy 7 karyotype
Comment
Clinical features of this disorder are [1-4]: short stature,
dolichocephaly, excessive number of neoplasms (see
below), characteristic facies (malar hypoplasia, prominent
nose, small mandible, protuberant prominent ears), UV
hypersensitivity of the skin (lesions appear mainly in the
face and back of hand/forearms), patchy
hyperpigmentation (café-au-lait spots) and areas of
hypopigmentation of the skin (predominantly on the trunk),
variable degree of vomiting and diarrhoea during infancy,
diabetes mellitus, azoospermia and early menopause,
immunodeficiency, average to low-average intelligence,
sometimes mental retardation. Cytogenetic studies show
increased sister-chromatid exchange and excessive number
of chromatid gaps and breaks. Neoplasms reported in
Bloom syndrome (in decreasing frequency): non-Hodgkin’s
lymphoma, skin cancer (predominantly basal cell type),
acute lymphocytic and acute myelocytic leukaemia, breast
cancer, colon (diagnosed as early as age 16 [5]) and rectal
cancer, oesophageal cancer, tongue cancer, laryngeal
cancer, cervical cancer and endometrial cancer, tongue
cancer, external auditory canal cancer, Wilms’ tumour,
osteogenic sarcoma, medulloblastoma and meningioma,
tonsillar cancer, retinoblastoma and myelodysplastic syndrome
(associated with monosomy  7 [6]). Wang et al. [7] reported
a 37-year-old man with ulcerative colitis complicated by
colon cancer. Lowy et al. observed colonic polyposis in a
Bloom syndrome patient [8]. More recently hepatocellular
cancer and vaginal cancer were reported [9, 10].
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Blue rubber bleb nevus syndrome
Synonym: Bean syndrome










leukaemia, chronic lymphocytic (CLL)




cutaneous nevi, haemangiomatous (blue rubber blebs)
Comment
The hallmarks of this disease are the presence of
multiple bladder-like haemangiomas (blue rubber blebs)
on the skin, especially on the trunk and arms. The
intestinal polypous haemangiomas may cause bleeding.
Haemangiomas may be found in a wide range of tissues
(spleen, lungs, joint capsules etc.) [1-3]. Chronic
lymphocytic leukaemia (at age 66) and renal cell cancer
(at age 57) were reported in a male with this disorder
[4]. Medulloblastoma was reported in a 21-year old
affected woman [5]. This condition may be identical to
familial venous malformation syndrome.
References
1. Laugier P. Blue rubber bleb nevus (author’s transl). Ann Dermatol
Venereol 1978; 105: 729-731.
2. Munkvad M. Blue rubber bleb nevus syndrome. Dermatologica
1983; 167: 307-309.
3. Morris SJ, Kaplan SR, Ballan K, Tedesco FJ. Blue rubber-bleb
nevus syndrome. JAMA 1978; 239: 1887.
4. Hoffman T, Chasko S, Safai B. Association of blue rubber bleb
nevus syndrome with chronic lymphocytic leukemia and
hypernephroma. Johns Hopkins Med J 1978; 142: 91-94.
5. Rice JS, Fischer DS. Blue rubber-bleb nevus syndrome.
Generalized cavernous hemangiomatosis or venous hamartoma
with medulloblastoma of the cerebellum: case report and review
of the literature. Arch Dermatol 1962; 86: 503-511.
Bone dysplasia with malignant change,
hereditary
Synonym: hereditary bone dysplasia with malignant
fibrous histiocytoma, diaphyseal medullary stenosis
with malignant fibrous histiocytoma, DMS-MFH
Mode of inheritance: AD
OMIM number: 112250
Genes:
DMSMFH/BDMF, mapped to 9p21-p22
Tumour features:





This disorder is characterized by bone dysplasia
presenting with diaphyseal medullary stenosis of
bone with overlying cortical bone thickening. The
epiphysis is not affected. The bone changes may not
appear until the 3rd or 4th decade of life. Other
features are fractures after minimal trauma and
malignant transformation (typically in 2nd-5th decade).
The neoplasms were originally classified as
fibrosarcomas, but later reclassified as malignant
fibrous histiocytomas. Approximately 35% of gene
carriers develop these malignant tumours. Early-
onset cataract was documented in some of the
patients and mental retardation was seen in 
a minority of cases [1, 2]. This syndrome maps to
9p21-22 [3, 4].
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Brain tumours, familial clustering of
Synonym: including familial medulloblastoma
Mode of inheritance: multifact?/AR?/AD?
OMIM number: 137800
Genes:
CYP2D6, mapped to 22q13.1
GSTM1, mapped to 1p13.3
GSTT1, mapped to 22q11.2
TP53, mapped to 17p13.1
Tumour features:
astrocytoma
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Familial occurrence of brain tumours has
predominantly been reported in sibs, but in some cases
the tumours have been found in successive generations
[1-5]. The most frequent tumours in these clusters are
astrocytoma, medulloblastoma [6, 7] and glioblastoma
[8]. Less frequently, choroid plexus papillomas [9],
ependymomas [10] and sarcomas [11] have been
reported. Figures on the percentage of brain tumours
that are familial are rare. Estimates for astrocytomas
range from less than 1 to 14% [12]. In the Swedish
Family-Cancer Database, which included 2060
childhood brain tumours, 1.3% of brain tumour
patients had a parent with nervous system cancer. Some
studies conclude that a family history of brain tumours
or cancer in general does not significantly contribute
to glioma risk in adults and brain tumour risk in
children [13-17]. Others found that the occurrence of
childhood brain tumour is associated with an increased
risk of developing central nervous system tumours,
leukaemia and childhood tumours in relatives [18-20].
One study found a particularly strong association
between parental meningioma and brain astrocytoma
in the offspring [20]. Malmer et al. [26] studied cancer
risk in the first-degree relatives of Swedish astrocytoma
patients and found an increased risk for astrocytomas
(relative risk 2.1) but not for other primary brain
tumours in these relatives.
Hill et al. reported that in individuals with a family
history of a brain cancer or a brain tumour, risk of
glioma was 1.6 and 3.0, respectively, in comparison
with those without such family histories. Increased risks
were also reported for a family history of stomach (RR
2.2), colon (RR 1.4), or prostate cancer (RR 2.1) or
Hodgkin’s disease (RR 2.4) [21]. In another paper they
reported that risk of meningioma was increased among
those with a family history of a benign brain tumour (RR
4.5) or melanoma (RR 4.2). A family history of breast
cancer was associated with an elevated meningioma
risk among participants aged 18 to 49 years (RR 3.9)
but a reduced risk among older individuals [22].
In general, the familial clustering of gliomas may
be associated with a range of congenital malformations
and is a genetically heterogeneous group [2]. Relatives
of patients with Ewing sarcoma or prostate cancer are
at increased risk of developing brain tumours [23, 24].
Significantly more colon cancer was observed in first-
degree relatives of children with brain tumours,
although absolute numbers were small [25].
Interestingly, another study reported a significant
decrease in colon (and breast) cancer risk for first-
degree relatives of astrocytoma patients [26]. Certain
variants of enzymes involved in (pro)carcinogen
metabolism have been found to be associated with an
increased risk of astrocytomas and meningiomas, e.g.
GSTT1, GSTM1 and CYP2D6 [27]. A small fraction of
familial clustering of gliomas may be attributed to
germline TP53 mutations [28-31].
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Breast cancer, familial clustering of
Mode of inheritance: multifact?
OMIM number: 114480
Genes many low penetrant gene mutations have been











Given the high risk of breast cancer in women [1],
familial occurrence of breast cancer is not rare. 
A family history of breast cancer has been reported in
14 to 30% of female breast cancer patients [2, 3].
Familial male breast cancer is rare [4-6]. Having 
a relative with breast cancer is one of the strongest risk
factors for this tumour [7-10]. A RR of 34.7 of
developing breast cancer has been reported in
monozygotic twins of women in whom breast cancer
had occurred before age 35 [11]. In general, the risk
of breast cancer in relatives does not appear to depend
heavily on the gender of their affected family member
[12-15]. Compared with the general population, breast
cancer is also found more frequently in women with
family history of ovarian, endometrial, colorectal
and/or prostate cancer and vice versa [16-24]. One
study reported a RR of 5.6 for parotid cancer in first-
degree relatives of breast cancer patients [25].
Depending on the number of affected relatives, the
degree of kinship and the age at onset of the tumours,
the empirical risk of developing breast cancer in 
a female relative may be close to 50% (even higher if
she already has children with breast cancer). Several
models have been developed to estimate breast cancer
risk in a specific family situation. Those by Gail et al.
[26-30], focussing on white females who are being
examined annually, and by Claus et al. [21, 31, 32]
are the ones most widely used in clinical practice. Users
should be aware of the specific limitations of these
models [33]. For example, the risk tables may need to
be adapted for use in different countries and or ethnic
groups to account for differences in genetic background
and exogenous risk factors [34]. The Claus model
includes first- and second-degree relatives, as opposed
to the Gail model, which looks at first-degree relatives
only. However, the latter method also takes into account
the risk factors of age at menarche, age at first live birth
and number of previous biopsies.
Given a positive or negative family history of breast
cancer, other known risk factors may differ in their
contribution to overall risk. Colditz et al. [35] reported
on an adverse effect of first pregnancy among women
with a family history of breast cancer that was
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approximately 50% greater in magnitude than among
women without a family history. Past use of oral
contraceptives and use of postmenopausal hormones
and history of benign breast disease showed similar
relative risks between the two groups. Sellers et al.
concluded the same with regard to hormone
replacement therapy in women with a family history of
breast cancer [36]. However, with respect to benign
breast disease, Dupont et al. [37] found that
fibroadenomas have an increased effect on breast
cancer risk in patients with a family history of breast
cancer compared to patients without a family history of
breast cancer. In addition, Skolnick et al. [38] analyzed
families with a clustering of breast cancer and suggested
that genetic susceptibility may cause both proliferative
benign breast disease and breast cancer in those
kindreds. Among women aged 30-49 years, a family
history of breast cancer was associated with an
increased risk of ductal carcinoma-in-situ (DCIS), and
among those aged 50 and older it was associated with
an increased risk of both DCIS and invasive breast
cancer [39]. Egan et al. [40] demonstrated a stronger
inverse association of high parity with breast cancer risk
in women who reported first-degree relatives with breast
cancer compared with women who did not have
affected first-degree relatives. In a study by Schouten 
et al. [41], family history of breast cancer was not
correlated with survival.
Chromosomes of breast cancer patients (and some
of their unaffected relatives) with a family history of
breast cancer are more sensitive to the action of the
mutagen bleomycin compared with sporadic breast
cancer patients [42], hinting at the involvement of
genes responsible for DNA repair.
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Byler disease
Synonym: PFIC-1, including Byler syndrome,
progressive familial intrahepatic cholestasis
Mode of inheritance: AR
OMIM number: 211600
Genes:







Byler disease is characterized by intrahepatic
cholestasis with an onset in infancy, leading to hepatic
fibrosis and death. It was originally described in an Amish
kindred. A similar disorder in children who are not members
of that kindred is referred to as Byler syndrome. Both
disorders are a subtype of progressive familial intrahepatic
cholestasis (another type is Alagille s.) [1]. Bull et al. [2]
concluded that Byler syndrome is heterogeneous from 
a clinicopathological point of view and is distinct from
Byler disease (which has been linked to 18q).
Hepatocellular cancer may develop as a compli-
cation of Byler disease/syndrome [3-5].
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Carcinoid, familial clustering of
Synonym: including carcinoid, intestinal
Mode of inheritance: multifact?/AD?
OMIM number: 114900
Tumour features:
carcinoid of the lung
gastrointestinal carcinoid
Comment
Anderson reported a father and daughter both
diagnosed with carcinoid of the appendix (at age 42
and 15 years, respectively) [1]. Moertel and Dockerty
[2] reported on a 2-generation family with (multiple)
intestinal carcinoids. One of the affected women
developed breast cancer at age 53 while her mother
had done so at age 47. Other tumours in that family
included nasopharyngeal fibrosarcoma (age 5) and
lung cancer (age 42), possibly suggesting Li-Fraumeni-
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like syndrome (see that entry). Additional cases of
familial intestinal carcinoids have been published 
[3-8] . An unknown proportion of these and other cases
of familial carcinoid might very well be caused by
germline mutations in MEN1, the gene associated with
multiple endocrine neoplasia type 1. Perkins et al. [9]
studied the family history of patients with carcinoid
tumours of the lung and demonstrated that the
proportion of distant metastasis in these patients was
significantly higher among those with a positive family
history of cancer (in general). Babovic-Vuksanovic et al.
[10] studied the occurrence of cancer in first-degree
relatives of 245 gastrointestinal carcinoid patients. For
first-degree relatives, only the risk for carcinoid was
increased (p<0.0001, life-time risk 1.5%).
Oliveira et al. reported pulmonary carcinoid in two
affected sibs and in a mother and daughter. No other
signs of MEN1 were present in these two families [11]. 
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Cardiac myxomas, familial clustering of
Mode of inheritance: AR?/AD?
OMIM number: 255960
Genes:




Familial cases of cardiac myxomas without further signs
of Carney complex (see that entry) have been reported. 
A high rate of recurrence is associated with these cases
[1]. Some families may carry a germline mutation in
PRKAR1A, the gene involved in Carney complex [2, 3]
and may be regarded as having a variant of that disorder.
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Mode of inheritance: sporadic (de novo)
OMIM number: 115150
Genes:
BRAF, mapped to 9q34
KRAS, mapped to 12p12.1
MEK1, mapped to 15q21












palpebral fissures, downward slanting
woolly, sparse and friable hair
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Comment
Hallmarks of CFC are a typical facies, congenital
heart defects (predominantly pulmonary stenosis and
ASD), growth failure and ectodermal anomalies. There
is clinical and molecular overlap with Noonan syndrome
and Costello syndrome. These disorders share disruption
of the RAS/MAPK signalling pathway [1-3].
Van den Berg and Hennekam [4] reported a 5-year-
old girl with CFC who was diagnosed with ALL and
Makita reported another case [5]. Bisogno et al. [6]
described a 20-month-old boy with CFC and an
(embryonal) rhabdomyosarcoma. A hepatoblastoma
was reported by Al-Rahawan [7].
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Carney complex
Synonym: Carney syndrome, NAME syndrome, LAMB
syndrome, familial myxoma syndrome
Mode of inheritance: AD
OMIM number: 160980
Genes:
CNC2, mapped to 2p15-p16
PRKAR1A, mapped to 17q22-q24
Tumour features:








schwannoma (neurilemmoma), peripheral nerve
schwannoma of the bone
schwannoma, psammomatous melanotic
schwannomas of the (posterior) spinal nerve roots
skin myxoma



















More than 200 patients have been reported, half of
them familial cases. Patients present with spotty multiple
small brown to black macules (lentiginosis) on the skin
and mucosae (67% of patients). Other pigmented
lesions are cafe-au-lait spots, (epithelioid) blue nevi (19%
of patients) and less frequently psammomatous
melanotic schwannoma (neurilemmoma) [1]. Primary
pigmented nodular adrenocortical disease (PPNAD)
leading to Cushing’s disease is also typical for the
syndrome (found in 33% of patients).
A range of tumours can be found in Carney
complex, including myxomas of the heart (in 30-61%
of patients), breasts (20%), skin (37%) (of the eyelids
in 25%) and external ear canal, testicular tumours
(30%): testicular large cell calcifying Sertoli tumours
(LCCST) and (less frequently) Leydig cell tumours,
growth hormone producing pituitary adenomas (11%)
and schwannomas of the upper GI tract, bone,
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sympatic chain and the skin (as mentioned above) 
(total % schwannomas found in Carney complex: 11).
Thyroid gland involvement is common (11%), ranging
from follicular hyperplasia to cancer [2-4]. Nwokoro
et al. [5] reported an affected 34-year-old woman from
a Carney complex family, who in addition to features
typical for this disorder also developed an atypical
mesenchymal tumour of the cervix, neoplastic colonic
polyps and Barrett’s oesophagus.
There is evidence for genetic heterogeneity in
Carney complex [4, 6-8]. In some families, linkage
analysis may help in identifying affected relatives [9].
Germline mutations in the PRKAR1A gene have been
detected in approximately 45% of Carney complex
cases and can also be found in isolated familial
myxoma and familial or isolated cases of PPNAD 
[10-12].
Criteria [4, 5, 13] – 2 of the following should be
present:
a) heart myxoma,
b) breast myxoma (myxoid mammary fibroadenoma),
c) skin myxoma,
d) primary pigmented nodular adrenocortical disease,
e) GH-secreting pituitary tumour,
f) psammomatous melanotic schwannoma (PMS),
g) ductal adenoma of the breast,
h) large-cell calcifying Sertoli cell tumour of the testes
(LCCST),
i) spotty pigmentation if it is: multiple, present in 
a characteristic distribution (vermilion border of the
lips, conjunctivae, external genitalia), not dependent
on exposure to sunlight, and has histology consistent
with lentigo rather than ephelide (freckle).
The presence of adrenocortical rest tumours is
regarded as corroboratory evidence for the diagnosis [12].
Unfortunately, the name Carney syndrome is used
by some to refer to the Carney complex, whereas others
use it to refer to Carney triad, which is a completely
different disorder. 
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Carney triad
Synonym: Carney syndrome











small intestine, stromal tumour of
Tumour features (possible):
exostoses
leiomyosarcoma of the uterus
parathyroid adenoma
renal angiomyolipomas
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Comment
The combination of gastric stromal sarcoma, extra-
adrenal paraganglioma and pulmonary chondroma
is referred to as the Carney triad. Carney reviewed the
79 reported cases [1]. Approximately 85% of Carney
triad patients are female. Age of onset ranged from 7
to 48 years (82% diagnosed before age 30); 78% of
the reported cases do not present with the complete
triad but show only 2 of the 3 features, the
paragangliomas being the least frequent component.
Although most cases are sporadic, 2 patients have
been reported each with a sibling who had one of the
tumours of the triad [1]. Gastric stromal sarcomas are
usually the presenting tumour. The name (epithelioid)
leiomyosarcoma was used in the past to refer to these
tumours, but smooth muscle markers have not been
identified in all cases; hence the change to ‘stromal
sarcomas’. The chondromas (diagnosed between 12
and 49 years) are multiple unilateral in 24% and
bilateral in 13% of cases and may be recognized more
than 15 years earlier and more than 20 years later
than the leiomyosarcomas. After surgery for the
chondromas, one or more new tumours developed in
56% of patients. The paragangliomas (diagnosed
between age 12 to 48 years) are generally
catecholamine secreting; they are present in multiple
sites in 22% and may undergo malignant change.
Silent adrenocortical adenomas were present in 13%
of the patients and are considered part of the disorder.
Other tumours observed were: oesophageal
leiomyoma and stromal tumour, duodenal (multiple)
stromal tumours, uterine leiomyosarcoma, bony
exostosis, renal angiomyolipoma, parathyroid
adenomas, gluteal myoma [1-7].
Unfortunately, the name Carney syndrome is used
by some to refer to the Carney triad, whereas others
use it to refer to Carney complex (or LAMB or NAME
syndrome), which is a completely different disorder.
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Caroli disease
Synonym: Caroli syndrome





cystic dilatations of intrahepatic bile ducts
Comment
This disorder is characterized by congenital
polycystic dilatation of the intrahepatic bile ducts [1].
It is frequently associated with autosomal recessive
polycystic kidney disease and congenital hepatic
fibrosis (in the latter case called Caroli syndrome
[2]), suggestive of a genetic overlap/allelism. There
exists a marked predisposition to the development
of cholangitis and liver abscesses. The clinical course
can be asymptomatic for the first 5 to 20 years.
Cholangiocarcinoma in the intrahepatic cystic lesions
has been reported in approximately 7% of cases 
[3-5].
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Cerebral sarcoma, familial clustering of
Mode of inheritance: multifact?/AR?/AD?
OMIM number: 117600
Tumour features:
brain, sarcoma of the
Comment
Gainer et al. [1] reported four cases of cerebral
fibrosarcomas occurring in two families: an affected
father (age at diagnosis 73 years) and daughter (at 59
years); and a family with two affected sisters (diagnosed
at age 64 and 69 years).
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Cerumen type





ear wax, wet (as opposed to the dry brittle type)
Comment
Different cerumen types exist [1]. Studies of mainly
the Japanese population have demonstrated two types
of ear wax inheriting as an autosomal dominant trait:
wet, sticky ear wax, or dry, brittle ear wax. A positive
association between wet ear wax and breast cancer
has been suggested, but data are presently inconclusive
[2-5].
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Cervical cancer, familial clustering of
Mode of inheritance: multifact?
Genes: various low penetrant gene mutations have
been reported, we do not list them separately here
Tumour features:
cervical cancer











Familial clustering of cervical cancer has been
reported [1-4]. An estimated 15% of patients with this
tumour have at least one affected first-degree relative
[1]. It has been calculated that having a first-degree
relative with cervical cancer is associated with a RR 
of 3 of developing squamous cell cancer of the cervix,
a RR of 10 of developing adenosquamous cancer at this
site and no increased risk of developing cervical
adenocarcinoma [1]. No other studies have confirmed
these detailed findings so far. Data from the Swedish
Family-Cancer Database showed a cervical cancer RR
of 2.0 for daughters of affected mothers [5]. In a more
recent and more detailed analysis the following figures
were reported [6]: daughters of mothers with in situ
cancer had a RR of 1.7 of developing in situ and RR of
again 1.7 of invasive cancer. Daughters of mothers with
invasive cervical cancer had a RR of 1.6 of developing
in situ cancer and a RR of 2.0 of developing invasive
cancer. The following other cancer types in mothers
increased the risk for in situ and/or invasive cervical
cancer in their daughters: lung, liver, urinary bladder
and oral cancer. The following cancer types in daughters
increased the risk for in situ and/or invasive cervical
cancer in their mothers: lymphoma, ovarian, oral, skin
and anorectal cancer.
An analysis of large Mormon families did not show
increased risks of cervical cancer in women with an
affected sister [7]. However, an excess of cervical cancer
was observed in first-degree relatives of patients with
early-onset bladder cancer (RR 2.32). A family history
of cancer in general was no risk factor for cervical
cancer in a Yugoslavian and a Japanese cohort [8, 9].
A study of Finnish patients with borderline ovarian
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tumours and their relatives demonstrated a RR of 7.8
for cervical cancer in the mothers of index cases [10].
In a Swedish twin study, the increase in risk of cervical
cancer tended to be greater if monozygotic rather than
dizygotic twins were affected [11].
Certain HLA haplotypes have been found in
association with an increased incidence of cervical
cancer or cervical intra-epithelial neoplasia in relation
to HPV infections [12-20]. Possibly, some of these HLA
types and other genotypes (e.g. P53, GSTT1, GSTM1
[21]) are linked to a less effective immunoresponse to
human papilloma virus (HPV) infections, a major risk
factor for this tumour [22, 23].
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Chediak-Higashi syndrome
Mode of inheritance: AR
OMIM number: 214500
Genes:











This disorder (CHS) is characterized by partial
oculocutaneous albinism, increased susceptibility to
bacterial infections due to impaired natural killer cell
activity, and the presence of massive lysosomal
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inclusions in all white blood cells and of giant
melanosomes in melanocytes. The majority of patients
develop a lymphoproliferative disorder during the
accelerated phase of the disease, which was
demonstrated by Argyle et al. [1] to be a NHL T-cell
lymphoma. The patients generally die in early
childhood due to recurrent infections, although a late-
onset type has been reported. An ovarian sclerosing
stormal tumour has been detected in a girl with CHS
[2]. The CHS gene has been identified [3].
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Cheilitis glandularis
Mode of inheritance: multifact?/AD?
OMIM number: 118330
Tumour features:
lip, squamous cell cancer of the
Non-tumour features:
lips, hypertrophy of the labial mucous glands
Comment
This disorder is characterized by chronic
inflammation of the labial salivary glands, resulting in
swelling, eversion and hypersecretion of the affected
lips (usually the lower lip) [1]. Swerlick and Cooper [2]
stated that the condition is not related to hyperplasia
of the labial salivary glands, but rather is the result of
an unusual reaction in response to chronic irritation of
the lips. A high incidence of lower lip squamous cell
cancer (in whites) is found in this disorder [3]. Possibly
lip eversion causes a higher sensibility/exposure to
carcinogens (rather than cheilitis glandularis itself being
a precancerous condition [4]) [5]. Familial cases have
been reported [5, 6].
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paraganglioma, nonchromaffin (including glomus
tumour/chemodectoma)
Comment
Lee et al. [1] reported a Maori family in which 
a 37-year-old man presented with multiple malignant
chemodectomas (para-aortic extending to the liver, and
tumours in the duodenum, pancreas, lungs and skull).
He also had multiple subcutaneous angiolipomas of
the limbs and abdominal wall. Two brothers had died
before the age of 45, cause unknown. One of them
was reported to have had multiple skin tumours.
Another, 40-year-old brother had similar skin tumours
and presented with a malignant chemodectoma
involving one of the kidneys and metastases in bones
and lungs.
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Cherubism
Synonym: familial benign giant-cell tumour of the jaw,
familial multilocular cystic disease
Mode of inheritance: AD
OMIM number: 118400
Genes:






jaw cysts associated with multinucleated giant cells
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lower face swelling
rib cysts associated with multinucleated giant cells
Comment
This benign self-limiting disorder is characterized
by swelling of the lower face, associated with multiple
cystic changes in the jaw and anterior end of ribs.
Biopsies of these skeletal lesions show multinucleated
giant cells. Onset is around the 3rd-4th year of life and
it progresses until the late teens [1-3]. Some cases may
behave very aggressively [4-6]. Mangion et al. reported
the occurrence of an osteosarcoma in the irradiated
jaw of one of their patients [7]. 
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CHIME syndrome
Mode of inheritance: AR
OMIM number: 280000
Tumour features (possible):




















This is a very rare disorder characterized by
colobomas of the eye, congenital heart defects,
migratory ichthyosiform rash of the skin, mental
retardation and ear defects (overfolding helices and
conductive deafness) (CHIME). Epilepsy, neonatal
macrosomia and craniofacial dysmorphisms are
additional features. Schnur et al. [1] reported a girl
with this disorder who developed acute lymphoblastic
leukaemia.
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